Abstract
Paget’s disease of Bone - Pipeline Assessment and Market Forecasts to
2017
Summary
GlobalData, the industry analysis specialist, has released its new report,
“Paget’s disease of Bone Pipeline Assessment and Market
Forecasts to 2017”. The report is an essential source of information and
analysis on the global Paget’s disease of Bone market. The report
identifies the key trends shaping and driving the global Paget’s disease
of Bone market. The report also provides insights on the prevalent competitive
landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global
Paget’s disease of Bone sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.
GlobalData’s analysis reveals that the Paget’s disease of bone
market was worth $678m in 2009. It is forecast to exhibit a negative compound
annual growth rate (CAGR) of 5% for the next eight years and is expected to
reach $463m by 2017. The negative growth rate is primarily attributable to the
patent expiry of major approved drugs and a weak pipeline for the indication.
Furthermore, a substantial decrease in the prevalence of Paget’s disease
of bone will lead to a drop in the global prescription population. The market
will witness generic erosion owing to the patent expiry of products such as
Actonel Reclast and Miacalcin. The market has been steadily declining over the
past few years and this trend is likely to continue
Scope
The report provides information on the key drivers and challenges of the
Paget’s disease of Bone market. Its scope includes:
- Annualized
global Paget’s disease of Bone market revenues data from 2001 to 2009,
forecast for eight years to 2017.
- Pipeline analysis data providing a
split across the different phases, mechanisms of action being developed and
emerging trends. Pipeline candidates fall under major therapeutic classes such
as Antagonist of Wnt Signaling and osteoclast activity inhibitor.
-
Analysis of the current and future competition in the global Paget’s
disease of Bone market. Key market player covered is Genta Incorporated.
-
Insightful review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide a qualitative analysis of its
implications.
- Key topics covered include strategic competitor
assessment, market characterization, unmet needs and the implications for the
Paget’s disease of Bone therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you
to:
- Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies and by identifying the
companies with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global Paget’s disease
of Bone market.
- Drive revenues by understanding the key trends,
innovative products and technologies, market segments and companies likely to
impact the global Paget’s disease of Bone market in future.
-
Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for consolidations,
investments and strategic partnerships.
- What’s the next big thing
in the global Paget’s disease of Bone market landscape? -
Identify, understand and capitalize.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2
Paget’s Disease of Bone: Market Characterization 4
2.1 Overview
4
2.2 GlobalData Pipeline Report Guidance 4
3 Paget’s Disease of
Bone Therapeutics Market: Market Characterization 5
3.1 Paget’s
Disease of Bone Therapeutics Market Size 5
3.2 Paget’s Disease of
Bone Therapeutics Market Forecast and CAGR 6
3.3 Drivers and Barriers for
the Paget’s Disease of Bone Therapeutics Market 7
3.3.1 Drivers for
the Paget’s Disease of Bone Therapeutics Market 7
3.3.2 Barriers of
the Paget’s Disease of Bone Therapeutics Market 7
3.4 Opportunity
and Unmet Need 8
3.5 Key Takeaway 9
4 Paget’s Disease of Bone
Therapeutics Market: Competitive Assessment 10
4.1 Overview 10
4.2
Strategic Competitor Assessment 10
4.3 Product Profile for the Major
Marketed Products in the Paget’s Disease of Bone Therapeutics Market
11
4.3.1 Risedronate sodium (Actonel) 11
4.3.2 Alendronate sodium
(Fosamax) 12
4.3.3 Zoledronic Acid (Reclast/Aclast) 13
4.3.4
Pamidronate Disodium (Aredia) 14
4.3.5 Tiludronate disodium (Skelid)
14
4.3.6 Salmon calcitonin (Miacalcin) 15
4.4 Key Takeaway 17
5
Paget’s disease of bone: Pipeline Assessment 18
5.1 Overview 18
5.2 Strategic Pipeline Assessment 18
5.2.1 Technology Trends Analytic
Framework 18
5.3 Paget’s disease of bone Therapeutics -
Promising Drugs under Clinical Development 20
5.3.1 Oral Gallium 20
5.4 Paget’s Disease of Bone Therapeutics Market - Clinical
Pipeline by Mechanism of Action 21
5.5 Paget’s Disease of Bone
Pipeline - Pipeline by Clinical Phases of Development 22
5.5.1
Paget’s Disease of Bone Therapeutics - Phase II Clinical Pipeline
22
5.5.2 Paget’s Disease of Bone Therapeutics - Preclinical
Pipeline 22
5.6 Discontinued / Suspended Drugs for Paget’s Disease
of Bone 22
5.7 Key Takeaway 22
6 Paget’s Disease of Bone
Therapeutics Market: Implications for Future Market Competition 23
7
Paget’s Disease of Bone Therapeutics Market: Future Players in the
Paget’s Disease of Bone Therapeutics Market 24
7.1 Introduction
24
7.2 Genta Incorporated 24
8 Paget’s Disease of Bone
Therapeutics Market: Appendix 26
8.1 Market Definitions 26
8.2 KOL
Interviews 26
8.3 Acronyms 26
8.4 Research Methodology 27
8.4.1
Coverage 27
8.4.2 Secondary Research 27
8.4.3 Forecasting 27
8.4.4
Primary Research 30
8.4.5 Expert Panel Validation 30
8.5 Contact Us
30
8.6 Disclaimer 31
8.7 Sources 31
1.1 List of Tables
Table 1: Paget’s Disease of Bone Therapeutics Market, Global, Revenue
($m), 2001-2009 5
Table 2 Paget’s Disease of Bone Therapeutics
Market, Global, Market Forecasts ($m), 2009-2017 6
Table 3:
Paget’s Disease of Bone Therapeutics Market, Strategic Competitor
Assessment of the Major Marketed Products, 2010 11
Table 4: Paget’s
Disease of Bone Therapeutics Market, Current Major Products, 2010 16
Table
5: Paget’s disease of bone Therapeutics - Promising Drugs Under
Clinical Development, 2010 20
Table 6: Paget’s Disease of Bone
Therapeutics - Phase II Clinical Pipeline, 2010 22
Table 7:
Paget’s Disease of Bone Therapeutics Market, Preclinical Pipeline, 2010
22
Table 8: Paget’s Disease of Bone Therapeutics Market, List of
Discontinued Drugs, 2010 22
1.2 List of Figures
Figure 1:
Paget’s Disease of Bone Therapeutics Market, Global, Revenues ($m),
2001-2009 5
Figure 2: Paget’s Disease of Bone Therapeutics
Market, Global, Revenue Forecasts ($m), 2009-2017 6
Figure 3: Opportunity
and Unmet Need in the Paget’s Disease of Bone Therapeutics Market 8
Figure 4: Paget’s Disease of Bone Therapeutics Market, Technology
Trends Analytic Framework of the Pipeline, 2010 19
Figure 5:
Paget’s Disease of Bone Therapeutics Market, Technology Trends Analytic
Framework of Pipeline, Description, 2010 19
Figure 6: Paget’s
Disease of Bone Therapeutics Market, Clinical Pipeline by Mechanism of Action
(%), 2010 21
Figure 7: Paget’s Disease of Bone Therapeutics
Market, Pipeline by Phase of Clinical Development (%), 2010 22
Figure 8:
Paget’s Disease of Bone Therapeutics Market, Global, Implications for
Future Market Competition, 2010 23
Figure 9: Paget’s Disease of Bone
Therapeutics Market, Clinical Pipeline by Company, 2010 24
Figure 10:
GlobalData Market Forecasting Model 29
